VacciNEWS – Page 20 – Global Health Press

GHP News Infographic

Varicella and Zoster (Shingles)

Download Infographic Overview A live attenuated vaccine against varicella (later also used to prevent zoster) was developed in 1974 by Takahashi and colleagues. The varicella vaccine was licensed for universal...

10 December, 2025

2 min read

GHP News Latest Science

ViVa 30 – Question of the Week (“YES or NO”) by OC

Question: I received Zostavax 10 years ago. Can I now get vaccinated with Shingrix? Answer: Yes. The Evidence. The study referenced below shows that the Shingrix is immunogenic and well-tolerated in older adults who had...

10 December, 2025

2 min read

GHP News Latest Science

Ebola virus disease – Democratic Republic of the Congo

The World Health Organization provides a detailed report on the Ebola virus disease (EVD) outbreak that occurred in the Bulape Health Zone of Kasai Province, Democratic Republic of the Congo (DRC), in 2025. The Ministry...

10 December, 2025

4 min read

GHP News Latest Science

New FDA guidelines – a response by experts in the field

In a NEJM Perspective, 12 former FDA commissioners warn that new internal FDA directives on vaccine regulation threaten evidence‑based policy, innovation, and public health. The piece responds to a memo by the current...

10 December, 2025

4 min read

GHP News Infographic

Vaccinating the immunocompromised host

Download Infographic Overview Infectious diseases (ID) are a major cause of morbidity and mortality in immunocompromised hosts (ICH). IDs may also trigger underlying conditions, graft-versus-host disease (GVHD), or...

4 December, 2025

1 min read

GHP News Latest Science

Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada

Critical Summary This article evaluates the cost-effectiveness of recently available respiratory syncytial virus (RSV) immunization options—nirsevimab (a long-acting monoclonal antibody) and the maternal RSVpreF...

4 December, 2025

4 min read

GHP News Latest Science

Safety and Immunogenicity of an rVSV Lassa fever vaccine candidate

Critical Summary The article by Malkin et al. presents the results of a phase 1, double-blind, randomized clinical trial evaluating the safety and immunogenicity of the rVSVΔG-LASV-GPC vaccine, a recombinant vesicular...

3 December, 2025

4 min read

GHP News Latest Science

The relationship between immunogenicity and reactogenicity of vaccines

This narrative review by Gromer et al. provides a comprehensive synthesis of the long-observed but poorly characterized relationship between vaccine reactogenicity—short-term, inflammatory adverse events—and...

3 December, 2025

4 min read

All Articles